Indication Tooltip

LORBRENA® (lorlatinib) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

  • that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
  • that has spread to other parts of the body, and
  • who have taken the medicine:
    • alectinib, or ceritinib, or
    • both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
  • that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

Uninsured

Help identifying resources for eligible patients without any form of healthcare coverage:

Help finding coverage

Medicare/Government Insured

Help identifying resources for eligible patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans:

Commercially Insured

Resources for eligible commercial, private, employer, and state health insurance marketplace patients:

Co-pay assistance

Eligible, commercially insured patients may pay as little as $0 per month for LORBRENA.* There are no income requirements, forms, or faxing to enroll.

Pfizer Oncology Together Call 1-877-744-5675 Visit PfizerOncologyTogether.com